Watch KTTAW. Know when insiders buy.
One email the day a filing lands. Free.
KTTAW
Pasithea Therapeutics Corp.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$21.3MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$5.7M | −$5.3M | — | -0.16 | −$4.7M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$4.9M | −$2.9M | — | -0.12 | −$4.8M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.3M | −$10.1M | — | -0.89 | −$5.4M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$3.1M | −$3M | — | -0.41 | −$2.9M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$3.8M | −$3.7M | — | -0.66 | −$3.9M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3.7M | −$3.6M | — | -1.61 | −$3.1M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.3M | −$3.2M | — | -2.41 | −$2.4M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$3M | −$3M | — | -2.87 | −$3.1M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$3.9M | −$3.9M | — | -3.71 | −$4M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$4M | −$3.9M | — | -3.70 | −$4.3M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.1M | −$5M | — | -0.40 | −$3.3M | −$36 | −$3.3M | Mar 24 |
| Q3 2023 · Sep 30 | — | — | — | −$3.8M | −$3.6M | — | 0.00 | −$3.2M | −$23K | −$3.2M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$20.9M | −$20.4M | — | -2.91 | −$15.2M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$14.2M | −$13.9M | — | -12.69 | −$13.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$16M | −$16M | — | -0.42 | −$12.8M | $34K | −$12.8M | $3.7M | — |
| FY2022 · to Dec 31 | $487K | 76.7% | −$12.6M | −$13.9M | -2864.3% | -1.76 | −$14.6M | $107K | −$14.7M | — | — |
| FY2021 · to Dec 31 | $15K | -14.7% | −$4.5M | −$2.2M | -14430.5% | -0.21 | −$3.2M | $22K | −$3.2M | — | — |
Every number comes from Pasithea Therapeutics Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.